Special Topic: Trading Alerts

**【Review of Major Events】** **SDIC Capital:** The valuation adjustment for the SDIC Silver Futures Securities Investment Fund is anticipated to have a certain negative impact on the net profit attributable to shareholders for the 2026 fiscal year. SDIC Capital announced that the valuation adjustment matter concerning the SDIC Silver Futures Securities Investment Fund (LOF), managed by its third-tier controlled investment enterprise SDIC UBS Fund Management Co., Ltd., has drawn market attention. SDIC UBS Fund released a specific work plan for the matter on February 15, 2026. Preliminary estimates indicate this plan is expected to negatively affect the company's 2026 net profit attributable to shareholders. The impact amount is less than 5% of the company's audited 2026 net profit attributable to shareholders and will not have a substantive impact on the overall business development.

***ST Jinglan:** The company may apply for a trading halt for verification if its stock price experiences further abnormal increases in the future. *ST Jinglan announced that its stock price increased by 86.90% between January 23, 2026, and February 13, 2026, representing a significant short-term rise. While the company's performance has not undergone major changes, the recent stock price has severely deviated from its fundamentals. Investors participating in trading may face substantial risks. If the stock price rises abnormally further, the company may apply for a trading halt for verification. Investors are advised to invest rationally and be aware of investment risks.

**MGI Tech:** Plans to sell 100% equity in CGI for approximately $50 million and adjust licensing agreements. MGI Tech announced that its wholly-owned subsidiary, MGI Tech R&D HONG KONG CO., LIMITED, signed a Share Purchase Agreement with Swiss Rockets AG. The agreement involves the sale of 100% equity in its wholly-owned subsidiary, Complete Genomics, Inc., to Swiss Rockets for approximately $50 million, with the final price subject to closing conditions. Additionally, the company's wholly-owned subsidiaries MGI US LLC and CGI signed an Amendment to the License Agreement with Swiss Rockets. This amendment adds a provision to the existing CoolMPS License Agreement to grant Swiss Rockets a paid license for the company's StandardMPS sequencing technology and universal sequencing technology.

**JiaYou International:** The Ndola to Sakania road section in Zambia officially commences commercial operation and begins toll collection. JiaYou International announced that on February 22, 2026, following joint inspection by relevant authorities and approval by the Zambian Cabinet, the 17.26-kilometer Ndola to Sakania road, toll stations, and related ancillary works in Zambia obtained the Practical Completion Certificate and the Toll Collection License. The project is now officially in commercial operation and has begun toll collection. The successful completion and commencement of tolling for this road section mark a significant milestone for the Zambian Sakania PPP project. It signifies a substantial transition from investment to operation for the company's first PPP project in Zambia, which will now generate stable revenue and facilitate the smoother and faster implementation of the remaining parts of the project.

**Asia Cuanon:** A 2.9165% stake in the company held by the controlling shareholder will be judicially auctioned. Asia Cuanon announced that it recently learned through public online channels that the Hangzhou Shangcheng District People's Court will conduct a judicial auction on its Taobao judicial auction platform from 10:00 on March 16 to 10:00 on March 17, 2026. The auction involves 12.5 million unrestricted tradable shares held by the controlling shareholder, Cuanon Ming, representing 2.9165% of the company's total share capital. As of now, Cuanon Ming holds 78.6555 million shares, representing 18.35% of the total share capital. This auction will not affect the company's production and operations nor result in the company's share distribution failing to meet listing requirements.

**Frontier Biotech:** Signs an exclusive licensing agreement with GlaxoSmithKline PLC. Frontier Biotech announced it has entered into an exclusive licensing agreement with the global biopharmaceutical company GlaxoSmithKline PLC. Under the agreement, GSK obtains exclusive global rights for the development, production, and commercialization of two small interfering RNA (siRNA) pipeline products. One candidate drug has entered the Investigational New Drug (IND) application stage, while the other is a preclinical candidate. Frontier Biotech will receive an upfront payment of $40 million and a near-term milestone payment of $13 million. The company is also eligible to receive up to an additional $950 million in success-based development, regulatory, and commercial milestones across the two programs, plus tiered royalties on global net sales. Frontier Biotech will be responsible for the early-stage development work, including advancing one product through Phase I clinical trials in China and completing IND-enabling studies for the other. GSK will be responsible for all subsequent global clinical development, regulatory submissions, and commercial activities for both products.

**Coco Healthcare:** Dismisses Jing Naiquan from his position as independent director. Coco Healthcare announced that the company's independent director, Mr. Jing Naiquan, has lost his independence, failed to fulfill his duties diligently, and lacks the professional integrity required of an independent director. Consequently, the board of directors determined that Mr. Jing is unsuitable to continue serving and proposed his dismissal. This matter has been reviewed and approved by the company's board nomination committee and the board of directors, and is subject to approval by the shareholders' meeting.

**【Performance Review】** **Risun Technology:** 2025 net profit reaches 84.2104 million yuan, a year-on-year increase of 31.87%. Risun Technology released an earnings report, stating that for 2025, it achieved total operating revenue of 468 million yuan, a year-on-year increase of 15.7%. Net profit attributable to shareholders of the listed company was 84.2104 million yuan, a year-on-year increase of 31.87%. Basic earnings per share were 0.8664 yuan. The growth in operating performance during the reporting period was primarily due to market expansion, new product development driving sales growth, cost reduction and efficiency improvements, and enhanced operational management efficiency.

**【Shareholding Changes】** **Topchoice Medical:** Chairman and others plan to increase their shareholdings by 6 million to 12 million yuan. Topchoice Medical announced that on February 13, 2026, Chairman Wang Yi increased his holdings by 10,500 shares, amounting to 499,600 yuan; Director Huang Yuhua increased holdings by 10,000 shares, amounting to 476,050 yuan; Board Secretary Zhang Hua increased holdings by 10,000 shares, amounting to 473,300 yuan; and other management member Zhao Min increased holdings by 7,700 shares, amounting to 367,100 yuan. The company's directors and senior executives plan to increase their collective shareholdings by no less than 6 million yuan and no more than 12 million yuan (including the amount increased on February 13, 2026) through centralized bidding transactions within six months from the date of this increase.

**Kede Numerical Control:** Controlling shareholder, actual controllers, and general manager commit not to reduce their shareholdings in the next 6 months. Kede Numerical Control announced that its controlling shareholder Guangyang Technology, actual controllers Yu Dehai and Yu Benhong, and General Manager Chen Hu have voluntarily committed not to reduce their direct or indirect holdings in the company in any manner for the next six months starting February 23, 2026. Any shares acquired during this commitment period due to stock dividends, capital reserve conversions, rights issues, etc., will also be subject to this no-sale commitment, excluding shares repurchased and cancelled by the company under equity incentive plans.

**【Share Repurchases】** **Luxshare Precision:** Conducts first share repurchase of 9.9006 million shares, utilizing nearly 500 million yuan. Luxshare Precision announced that on February 13, 2026, the company conducted its first share repurchase, buying back 9.9006 million shares via the special securities account for share repurchases through centralized bidding. This represents 0.14% of the total share capital as of February 12, 2026. The highest transaction price was 50.91 yuan per share, the lowest was 50.14 yuan per share, and the total transaction amount was nearly 500 million yuan (excluding transaction fees).

**【Major Contract Awards】** **Shuangliang Energy Systems:** Subsidiary wins 100 million yuan contract for H-class combined cycle power plant project. Shuangliang Energy Systems announced that its wholly-owned subsidiary, Jiangsu Shuangliang Cooling System Co., Ltd., recently won the bid for the air-cooled condenser system of an H-class combined cycle power plant project in the Middle East. The estimated contract value is 100 million yuan, accounting for 0.77% of the company's audited operating revenue for 2024. The main project scope includes the design, procurement, construction, and commissioning of the combined cycle power plant.

**Donghong Co., Ltd:** Wins 353 million yuan contract for pressure steel pipes and fittings project. Donghong Co., Ltd. announced that it recently received a notice of award, confirming the company as the winning bidder for a pressure steel pipes and fittings procurement project, with a contract value of 353 million yuan.

**Gold Mantis:** Subsidiary wins project for the Intercontinental Resort Hotel in Sabah, Malaysia. Gold Mantis announced that its subsidiary, Gold Mantis Construction Decoration (Malaysia) Sdn. Bhd., as a nominated subcontractor by the owner, has successfully won the project for the Intercontinental Resort Hotel in Sabah, Malaysia. The contract amount is approximately 281 million yuan, representing 1.53% of the company's audited operating revenue for 2024. The project is expected to positively impact the company's business development and operating performance, enhancing its brand influence and market recognition in the overseas high-end hotel decoration sector.